RS6 is a herpes simplex virus intertypic recombinant derived from type 1 strain 17 syn+ and type 2 strain HG52. With a 50% lethal dose of about 105 PFU after intracerebral inoculation of mice, RS6 was approximately 100,000 times less neurovirulent than either of its wild-type parental viruses were. When compared with strains 17 syn+ and HG52, RS6 replicated intermediately in primary mouse embryo fibroblasts in vitro at 38.5°C (mouse temperature) and to wild-type peak titers in mouse feet in vivo. In contrast, following intracranial inoculation of mice, RS6 replicated significantly less well than did either of its parental viruses in brains. The genetic defect(s) responsible for the reduced neurovirulence of RS6 (i) was stable after in vitro and in vivo serial passage, (ii) was not manifested as temperature-sensitive plaquing in vitro, and (iii) did not affect thymidine kinase expression. These data indicate that RS6 has a genetic defect(s) specifically affecting its ability to replicate in the mouse brain. Using marker rescue technologies, we increased the neurovirulence of RS6 and localized one genetic determinant(s) involved with the reduced neurovirulence of this agent to 0.72 to 0.87 map units (and, tentatively, to 0.79 to 0.83 map units) of the herpes simplex virus genome. When coupled with the work suggesting that thymidine kinase expression is essential for efficient replication in nerve tissues and earlier reports from this laboratory and others, the results presented in this study indicate that more than one herpes simplex virus gene is involved with neurovirulence.
The mouse is commonly used as a model system for studying acute herpes simplex virus (HSV)-induced encephalitis. In this system, intracerebral inoculation of a very low dose (1 to 10 PFU) of a standard HSV type 1 (HSV-1) or type 2 (HSV-2) leads to acute fatal encephalitis (14) . HSV variants that require significantly larger doses to elicit fatal encephalitis are potentially useful for identifying viral genes and gene products associated with this disease. Two classes of such agents have been distinguished (25) . The first and most common class displays generalized replication defects in most cell types in vitro and in vivo. The second class of virus, on the other hand, replicates efficiently in most cell types in vitro and in vivo but exhibits a reduced ability to replicate in brain cells in vivo. This result indicates that there are genes which enable HSV to replicate efficiently in the central nervous system. Thus, with the use of specificneurovirulence mutants, HSV genes and gene products associated with acute central nervous system disease can be identified and mechanisms can be established.
In this paper, we biologically characterize the HSV-1 x HSV-2 intertypic recombinant RS6, a low-neurovirulence mutant which was found to display replication defects specific for the mouse brain in vivo. Then, using the cloned HSV-1 EcoRI e+k fragment in marker rescue experiments, we localized a genetic lesion(s) of RS6 to 0.72 to 0.87 map units (m.u.) of the HSV genome. Additional results suggest that 0.79 to 0.83 m.u. is the region involved.
MATERIALS AND METHODS Cells, viruses, and mouse inoculation. The techniques of tissue culture of rabbit skin cells, production of primary mouse embryo fibroblasts (MEF) , and infection, propagation, titration, and plaque purification of viruses have been described previously (25, 26) . The standard laboratory viruses HSV-1 17 syn+ and HSV-2 HG52 (21), TK-7 (a thymidine kinase (tk)-negative mutant derived from 17 syn+), and the intertypic recombinant RS6 were kindly provided by colleagues at the Medical Research Council Virology Unit, Glasgow, Scotland. RS6 was generated by cotransfection of unit-length tsS (a temperature-sensitive [ts] mutant of 17 syn+) DNA and XbaI-generated DNA fragments derived from HG52 (20) , and its genomic structure has been described previously (6, 13, 20) . Examination of comparative viral replication kinetics and the production of tk by the Ara-T test (22) were as described earlier (25) . The tk assay was that used by Cheresh and Haines (4), except that cellular cytoplasmic extracts were derived from LM(TK-) cells (10) lysed by two cycles of freeze-thaw at 14 h postinfection. Except where noted, 4-to 5-week-old outbred male Swiss Webster mice were used in all experiments, and standard procedures for intracranial inoculation (25, 26) and quantitation of neurovirulence (15) were used.
Restriction enzyme analysis and transfections. Isolation of DNA used for restriction endonuclease and Southern blot analyses were performed as described earlier (26) , except that viral DNA was layered onto sodium iodide gradients rather than onto cesium chloride for isopycnic centrifugation. The restriction endonucleases Asp718 (KpnI isoschizomer), BamHI, HindIII, and HpaI were used to analyze the genomic structures of putative recombinant viruses. Methods for transfection and isolation of unit-length RS6 DNA for transfection have been previously detailed (8, 19, 26) . In this study, however, transfections were performed without the use of carrier DNA, a modification which greatly increased the number of plaques normally obtained during transfection of unit-length RS6 DNA. Electroelution of XbaI fragments b, c, and f derived from HSV-1 17 syn+ was performed by standard methods (12 (20) . To eliminate the possibility that RS6 exhibited low neurovirulence because of a ts mutation affecting general viral replication, a comparison of its plaquing efficiencies at 31 and 38.5°C was performed. For this purpose, approximately 100 PFU of RS6 was plated onto cultured rabbit skin cells or primary MEF, and parallel flasks of each were incubated, with an anti-HSV antibody overlay (18), at either 31 or 38.5°C (mouse temperature). At 72 h postinfection, plaques were counted, and RS6 demonstrated 38.5°C/31°C plaquing ratios of 1 on both rabbit skin cells and primary MEF, a result indicating that ts mutations for replication were not responsible for the reduced neurovirulence of RS6. Expression of the enzyme tk. Since production of the enzyme tk by HSV has been implicated for complete expression of neurovirulence (7), tk enzyme assays (4) and Ara-T tests (22) were performed to test whether RS6 efficiently expressed this enzyme.
In the tk enzyme assay, RS6, 17 syn+ (a highly neurovirulent and tk-positive HSV-1 strain) and TK-7 (a weakly neurovirulent and tk-negative mutant) were used. LM(TK-) cells in monolayer were mock infected or infected with RS6, 17 syn+, or TK7 at a multiplicity of infection of 1 PFU per cell, and following adsorption for 1 h, the infection proceeded for 14 h. Cells were then harvested and lysed, and a tk assay was performed on the cytoplasmic extracts. The results of this assay (Table 1) indicate that RS6 expressed wild-type levels of HSV-specific tk. These results were confirmed in an Ara-T test, in which replication of RS6 and 17 syn+ was decreased more than 10,000-fold in the presence of the drug, while the replication of TK-7 was unaffected (data not shown).
RS6, 17 syn+, and HG52 replication in mouse tissues in vivo and in vitro. We next tested the likely possibility that the cause of the low neurovirulence of RS6 was inefficient replication in the mouse brain. Samples (105 PFU) of RS6, 17 syn+, or HG52 were inoculated into the left cerebral hemispheres of 4-to 5-week-old outbred male Swiss Webster mice. At 0, 12, 24, 48, 72, and 96 h postinfection, surviving mice were sacrificed, and their brains were removed and frozen at -70°C until assayed for virus. The results of this experiment show that RS6 replicated significantly less well than either of its parental viruses did in the mouse brain in vivo (Fig. 1A) .
To ascertain whether the brain cell replication deficiency of RS6 was specific or generalized to all mouse cells at the temperature of a mouse (38.5°C), a comparative multistep replication study was performed in primary MEF in vitro at 38.5°C. MEF monolayers 1 day old were infected at a multiplicity of infection of 0.001 PFU per cell with RS6, 17 syn+, or HG52, and at 0, 24, 48, 72, and 96 h postinfection, cells were harvested and frozen at -70°C until assayed for virus. RS6 displayed intermediate replication kinetics in MEF (Fig. 1B) , a result which likely reflects the hybrid nature of RS6. These results strongly suggest that RS6 is not replication defective for mouse cells in general at the temperature of a mouse.
In an extension of these studies, we also examined the replication of RS6, 17 inoculated onto both rear footpads of mice as described previously (4, 21) . At 0, 1, 3, 5, 7, and 9 days postinfection, mice were sacrificed, and their feet were removed and stored at -70°C until assayed for virus. The results indicate that RS6 replicated and peaked to titers comparable to its wildtype counterparts (Fig. 1C) ; however, beyond 3 days postinfection, RS6 did not sustain viral titers like those of 17 syn+ and HG52. This result has been observed previously (23) and may represent the lack of virus passing centrifugally from acutely infected nerve tissue of the ganglia to the foot (17) .
Phenotypic stability of RS6 after brain passage and transfection. The stability of the low-neurovirulence phenotype of RS6 was next examined (9) . A lethal dose of RS6 (_ 106 PFU) was inoculated into the brain of a mouse, and when the mouse died (24 to 48 h postinfection), its brain was removed and homogenized, and the recovered virus was passed to rabbit skin cells in culture to boost the titer. This procedure was repeated eight times, and when the neurovirulence of passage 8 virus was tested, its LD50 (3.0 x 105 PFU) after intracerebral inoculation of mice was similar to that of the parental RS6, i.e., 1.2 x 105 PFU.
Finally, since transfection of DNA into mammalian cells is known to be mutagenic (2), we transfected unit-length RS6 DNA alone onto five independent plates, harvested the viruses (_.106 PFU/0.1 ml), and inoculated these viruses intracerebrally into mice. The brain homogenates (cleared by centrifugation at 3,000 x g for 5 min in a Sorvall SS-34 rotor) of mice killed by encephalitis were then inoculated into another group of mice. All mice invariably survived this second brain injection. Nevertheless, an RS6 isolate, one for each of the five independent transfection plates, was plaque purified from the brains of the mice at 4 days postinfection. When LD50s following intracerebral inoculation were determined for each of the five independent isolates, they ranged from 1.0 a Mice were inoculated with serial 10-fold dilutions of each virus, and deaths from encephalitis were scored for 21 days postinfection. LD50s were determined by using the method of Reed and Muench (15) . length RS6 DNA and total genomic XbaI fragments derived from the highly neurovirulent HSV-1 17 syn+. Our rationale was that if a genetic lesion(s) of RS6 resided within or near one of its type 2-encoded regions, all resulting viruses with increased neurovirulence would display a total or partial replacement of this type 2 region with type 1 DNA of 17 syn+. If, on the other hand, a genetic lesion(s) of RS6 resided solely within type 1-encoded regions, this would be indicated by the isolation of neurovirulence-enhanced viruses resembling RS6 in structure.
From the cotransfection of unit-length RS6 DNA with 17 syn+ total genomic XbaI fragments, 6 of 20 transfection plates contained neurovirulence-enhanced viruses. When these viruses were plaque purified, one from each infected brain, they were found to exhibit wild-type or near-wild-type neurovirulence ( Table 2) . As determined by restriction endonuclease analysis using four different enzymes (Asp718, BamHI, Hindlll, and HpaI), four of these six viruses (X3-1, X3-9, X3-13, and X3-14) were shown to be recombinants, and except for minor differences, the restriction enzyme profiles of the other two (X3-20 and X10-13) resembled the DNA donor virus 17 syn+ (data not shown). Although each of the six neurovirulence-enhanced viruses had different genomic structures, they all shared two genomic changes (Fig. 2), (Fig. 4) . Therefore, the regions located from approximately 0.11 to 0.14 m.u. and 0.79 to 0.83 m.u. were tentatively associated with the low-neurovirulence characteristics of RS6.
(ii) RS6 DNA cotransfected with electroeluted HSV-1 XbaI fragments. To confirm and extend the observation that all recombinant viruses with increased neurovirulence displayed replacement of type 2 DNA with type 1 DNA at approximately 0.11 to 0.14 and 0.79 to 0.83 m.u., we electrophoretically purified XbaI fragments of 17 syn+ spanning these regions and used them in cotransfection experiments with unit-length RS6 DNA. Two (viruses BCF1 and BCF2) of five transfection plates of unit-length RS6 DNA cotransfected with the XbaI DNA b (0 to 0.07 and 0.77 to 1.0 m.u.), c (0.07 to 0.29 m.u.), and f (0.29 to 0.45 m.u.) fragments and one (virus BC3) of five transfection plates of unit-length RS6 DNA cotransfected with the XbaI DNA b and c fragments contained viruses with increased neurovirulence. The LD50s of these viruses after intracerebral inoculation of mice indicated that BCF1 and BC3 were 81-and 46-fold, respectively, more virulent than RS6 was, while BCF2 displayed wild-type neurovirulence (data not shown). The Asp718 restriction enzyme profiles of RS6, BCF1, 1C3, and 17 syn+ (Fig. 5) indicate that viruses BCF1 and BC3 gained a novel band in the 17 syn+ Asp718 e, f, and g triplet region, and as before, this was found to be associated with the acquisition of the 17 syn+ Asp718 g fragment (data not shown); highly neurovirulent recombinant virus BCF2 possessed extensive genomic replacements of RS6 type 2 regions with type 1 DNA and was not characterized further. Neurovirulence-enhanced viruses BCF1 and BC3 were more interesting than were any of the original six neurovirulence-enhanced viruses discussed above, however, because the only genomic differences of BCF1 and BC3 from RS6 were within the two adjacent type 2 regions at 2 region at 0.79 to 0.83 m.u. To lend support to this 0.79 to 0.83 m.u. and 0.83 to 0.85 and 0.99 to 1.0 m.u.; no hypothesis, we next used a cloned fragment, 17 syn+ EcoRI changes in the region 0.11 to 0.14 m.u. were evident for e+k (0.72 to 0.87 m.u.), which spans the region of interest. either virus. In fact, for virus BC3 the only evident differ- transfected alone. Viruses RB1, RB3, and RB4 were then JOINr inoculated intracerebrally into mice to determine their LD50s; they were all more neurovirulent than RS6 was 11_ _ 1 1 : - (Table 3) . Restriction enzyme analysis with Asp718 revealed xiz 4 I W±that RB1, RB3, and RB4 were recombinants which also displayed a novel band in the Asp718 e, f, and g triplet region With respect to related studies, this laboratory has previously reported the characterization of another intertypic recombinant, RE6, which is also a specific-neurovirulence mutant (25) . The gene associated with the nonneurovirulence of RE6 was mapped to 0.71 to 0.83 m.u. of the HSV genome (24, 26) , and it could be suggested that RS6 and RE6 have a genetic lesion in common 
